Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 15

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 15
---
 ENTYVIO, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: ALUNBRIG, FRUZAQLA

Vaccines: QDENGA

#### Core Operating Profit
Core Operating Profit for the fiscal year ended March 31, 2025 was JPY 1,162.6 billion (JPY +107.8 billion and +10.2% AER, +4.9% CER ) . The components of Core Operating Profit are as below:

| 2024                                                     |     | For the fiscal year ended 
 March 31,                 |     | 2025 |          |     | Amount of Change |     |          |     | AER      
 % Change |     |        |     | % Change |     |      |   | CER |     |      | Billion JPY or percentage |
|:---------------------------------------------------------|:----|:--------------------------|:----|:-----|---------:|:----|:-----------------|:----|---------:|:----|:---------|:----|-------:|:----|:---------|:----|-----:|:--|:----|:----|-----:|:--------------------------|
| Core revenue                                             |     |                           |     |      |  4,263.8 |     |                  |     |  4,579.8 |     |          |     |  316.1 |     |          |     |  7.4 | % |     |     |  2.8 | %                         |
| Core cost of sales                                       |     |                           |     |      | -1,426.3 |     |                  |     | -1,581.8 |     |          |     | -155.5 |     |          |     | 10.9 | % |     |     |  6.6 | %                         |
| Core selling, general and administrative (SG&A) expenses |     |                           |     |      | -1,053.0 |     |                  |     | -1,105.0 |     |          |     |  -52.1 |